Bokf Na Invests $26,000 in Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Bokf Na purchased a new position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) in the second quarter, Holdings Channel.com reports. The institutional investor purchased 11,905 shares of the biopharmaceutical company’s stock, valued at approximately $26,000.

A number of other large investors also recently bought and sold shares of ESPR. CVI Holdings LLC purchased a new stake in Esperion Therapeutics in the first quarter worth $37,000. Simplicity Wealth LLC purchased a new position in Esperion Therapeutics in the 1st quarter worth about $44,000. Sivia Capital Partners LLC bought a new stake in Esperion Therapeutics during the 2nd quarter valued at about $44,000. National Bank of Canada FI boosted its position in Esperion Therapeutics by 115.9% in the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 10,225 shares during the period. Finally, State Board of Administration of Florida Retirement System bought a new position in Esperion Therapeutics in the 1st quarter worth about $50,000. Hedge funds and other institutional investors own 47.39% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on ESPR. StockNews.com downgraded shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, September 11th. Bank of America cut Esperion Therapeutics from a “neutral” rating to an “underperform” rating and lowered their target price for the stock from $2.90 to $2.50 in a report on Thursday, June 20th. HC Wainwright reissued a “buy” rating and set a $16.00 price target on shares of Esperion Therapeutics in a research report on Monday, August 12th. Finally, Needham & Company LLC decreased their price objective on Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, August 13th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $8.17.

Esperion Therapeutics Stock Up 1.1 %

Shares of NASDAQ:ESPR opened at $1.78 on Wednesday. The firm has a 50 day moving average of $2.03 and a 200 day moving average of $2.24. The company has a market capitalization of $337.24 million, a price-to-earnings ratio of -1.80 and a beta of 1.00. Esperion Therapeutics, Inc. has a 52 week low of $0.70 and a 52 week high of $3.40.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.10. The company had revenue of $73.83 million during the quarter, compared to the consensus estimate of $51.90 million. On average, sell-side analysts expect that Esperion Therapeutics, Inc. will post -0.04 EPS for the current year.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.